ClinicalTrials.gov record
Completed Phase 1 Interventional

BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors

ClinicalTrials.gov ID: NCT00346385

Public ClinicalTrials.gov record NCT00346385. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 6:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I, Open-Label, Dose Escalation Study of Daily Dosing With BB-10901

Study identification

NCT ID
NCT00346385
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
ImmunoGen, Inc.
Industry
Enrollment
97 participants

Conditions and interventions

Interventions

  • BB-10901 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2002
Primary completion
Sep 30, 2011
Completion
Sep 30, 2011
Last update posted
Mar 25, 2015

2002 – 2011

United States locations

U.S. sites
6
U.S. states
6
U.S. cities
6
Facility City State ZIP Site status
University of California San Francisco San Francisco California 94115
Nevada Cancer Institute Las Vegas Nevada 89135
The Ohio State University Cancer Center and Research Institute Columbus Ohio
Oklahoma University Oklahoma City Oklahoma 73104
M. D. Anderson Cancer Center at University of Texas Houston Texas 77030-4009
Fred Hutchinson Cancer Research Center Seattle Washington 98109-1023

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00346385, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 25, 2015 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00346385 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →